Thermo Fisher Scientific (NYSE:TMO) Issues FY 2026 Earnings Guidance

Thermo Fisher Scientific (NYSE:TMO) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 24.930-25.330 for the period, compared to the consensus earnings per share estimate of 24.850. The company issued revenue guidance of $47.4 billion-$48.1 billion, compared to the consensus revenue estimate of $47.8 billion.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price for the company. Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a report on Thursday, May 14th. Finally, HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their target price for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $606.45.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $573.43 on Friday. The stock has a 50 day moving average price of $491.42 and a 200 day moving average price of $513.08. The stock has a market cap of $213.10 billion, a PE ratio of 31.52, a P/E/G ratio of 2.33 and a beta of 0.87. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific has a one year low of $435.27 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the company earned $4.28 EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insiders Place Their Bets

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher reported Q2 adjusted EPS of $6.03, above the $5.71 estimate, on revenue of $11.99 billion versus $11.71 billion expected, which supports the stock’s recent gains. Thermo Fisher beats quarterly estimates as customer demand improves
• Positive Sentiment: The company raised FY 2026 EPS guidance to $24.93-$25.33 and revenue guidance to $47.4 billion-$48.1 billion, suggesting management sees demand holding up better than previously expected. Thermo Fisher Scientific Launches Thermo Scientific InstaFlux
• Positive Sentiment: Organic revenue grew 5% and sales rose 10.5% year over year, with strength in laboratory products and biopharma services, reinforcing the view that end-market activity is improving. TMO Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Thermo Fisher also launched InstaFlux, a new workflow tool for food microbiology labs, which could support long-term product momentum but is not likely the main near-term stock driver. Thermo Fisher Scientific Launches Thermo Scientific InstaFlux

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $28,000. Birchwood Financial Partners Inc. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at about $29,000. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter valued at about $28,000. Wilkerson Advisory Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $48,000. Finally, Osterweis Capital Management Inc. boosted its position in shares of Thermo Fisher Scientific by 151.4% during the 3rd quarter. Osterweis Capital Management Inc. now owns 88 shares of the medical research company’s stock worth $43,000 after purchasing an additional 53 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.